Subcutaneous Lymphoma

This entry looks at subcutaneous lymphoma, one of those subtypes of lymphoma. 'Lymphoma' is an umbrella term that loosely refers to several dozen independent categorical types and subtypes of cancers of the lymphatic system. However, as a term, subcutaneous lymphoma is simply a shortened version of subcutaneous panniculitis-like T cell lymphoma or SPTCL.

This subcutaneous lymphoma is considered an extra-nodal lymphoma. It is extremely rare, representing about one percent of all skin-associated T cell lymphomas. All T cell lymphomas put together only represent 15% of ALL lymphomas, and there are fewer cutaneous lymphomas than peripheral ones. I don't have a reliable number handy, but the annual number of diagnoses of this rare subtype surely does not even come close to four figures.

Subcutaneous lymphoma has only recently been classified as its own entity, meaning that there is precious little reliable data on it. The 5 year relative survival rate is rather high at 82%, likely because this is a disease with an indolent clinical course—it grows very slowly. That said, there is a variant of the disease that is extremely aggressive, and this variant can be identified through molecular analysis.

Symptoms of Subcutaneous Lymphoma

Symptoms of subcutaneous panniculitis-like T cell lymphoma include so-called nodules, plaques or ulcers developing just under the skin. Diagnosis is not easy because its early symptoms are known to be mistaken for skin conditions that are more common, such as eczema, dermatitis, psoriasis and cellulitis. In certain cases, patients may develop more common lymphoma-like symptoms, such as weight loss, fevers and chills.

Treatment for Subcutaneous Lymphoma

Treatment in the past for subcutaneous lymphoma has been with combination chemotherapy that included doxorubicin (i.e. CHOP) along with radiation. However, emerging research suggests that corticosteroids may be just as effective at managing the disease without doing the damage that chemotherapy and radiation can often do.

Sources

MedScape Subcutaneous Panniculitis-like T-cell Lymphoma

Bagheri F et al. An illustrative case of subcutaneous panniculitis-like T-cell lymphoma. J Skin Cancer. 2011;2011:824528.

Hogue SR et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003 Mar;148(3):516-25.

Clinical Options, Relative Frequency and Disease-Specific 5-Year Survival Rates of Patients With Primary CTCL.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap